|
|
|
|
|
| de Oliveira Uehara,Silvia Naomi; Emori,Christini Takemi; Perez,Renata Mello; Mendes-Correa,Maria Cassia Jacintho; de Souza Paiva Ferreira,Adalgisa; de Castro Amaral Feldner,Ana Cristina; Silva,Antonio Eduardo Benedito; Filho,Roberto José Carvalho; de Souza e Silva,Ivonete Sandra; Ferraz,Maria Lucia Cardoso Gomes. |
| Abstract Brazil is one of the 22 countries that concentrates 80% of global tuberculosis cases concomitantly to a large number of hepatitis C carriers and some epidemiological risk scenarios are coincident for both diseases. We analyzed tuberculosis cases that occurred during α-interferon-based therapy for hepatitis C in reference centers in Brazil between 2001 and 2012 and reviewed their medical records. Eighteen tuberculosis cases were observed in patients submitted to hepatitis C α-interferon-based therapy. All patients were human immunodeficiency virus-negative. Nine patients (50%) had extra-pulmonary tuberculosis; 15 (83%) showed significant liver fibrosis. Hepatitis C treatment was discontinued in 12 patients (67%) due to tuberculosis reactivation and... |
| Tipo: Info:eu-repo/semantics/other |
Palavras-chave: Hepatitis C; Tuberculosis; Alpha-interferon; Latent tuberculosis infection. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702016000200205 |
| |
|
|
| Bilar,Juliana Miguel; Carvalho-Filho,Roberto José; Mota,Carolina Frade Magalhães Girardin Pimentel; Fucuta,Patricia da Silva; Ferraz,Maria Lucia Cardoso Gomes. |
| Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30-50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy, but it is associated with an increased incidence of adverse events. We herein report a case of acute pancreatitis developed during treatment with pegylated interferon, ribavirin and boceprevir. Boceprevir was the most likely cause of drug-associated pancreatitis after the most common causes were ruled out, since this adverse event had not occurred when the patient had previously been exposed to pegylated interferon and ribavirin and there was no recurrence of the episode of pancreatitis when these two... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Hepatitis C; Protease inhibitor; Side effect. |
| Ano: 2014 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000400454 |
| |
|
|
|
